91Ö±²¥

All publications

Journal articles

• Leaviss J, Carroll C, Essat M, van der Windt D, Grainge MJ, Card T, Riley R & Abhishek A (2024) . RMD Open, 10(1).
• Scope A, Leaviss J, Booth A, Sutton A, Parry G, Buszewicz M & Moss-Morris R (2021) . Br J Health Psychol, 26(4), 1069-1094.
• Carlton J, Leaviss J, Pouwer F, Hendrieckx C, Broadley MM, Clowes M, McCrimmon RJ, Heller SR & Speight J (2021) . Diabetologia, 64(6), 1213-1225.
• Thomas C, Brennan A, Goka E, Squires HY, Brenner G, Bagguley D, Buckley Woods H, Gillett M, Leaviss J, Clowes M , Heathcote L et al (2020) . BMJ Open, 10(9), e037486.
• Leaviss J, Davis S, Ren S, Hamilton J, Scope A, Booth A, Sutton A, Parry G, Buszewicz M, Moss-Morris R & White P (2020) . Health Technol Assess, 24(46), 1-490.
• Bessey A, Chilcott J, Leaviss J, de la Cruz C & Wong R (2019) . International Journal of Neonatal Screening, 5(3).
• Bessey A, Chilcott JB, Leaviss J & Sutton A (2018) . Orphanet J Rare Dis, 13(1), 179-179.
• Sutton AJ, Galvan De La Cruz MC, Leaviss J & Booth A (2017) . Research Synthesis Methods.
• Sutton A, de la Cruz MDCG, Booth A & Leaviss J (2017) . International Journal of Technology Assessment in Health Care, 33(S1), 242-242.
• Kearns B, Rafia R, Leaviss J, Preston L, Brazier JE, Palmer S & Ara R (2017) . BMC Health Services Research, 17(1), 78-78.
• Sammy IA, Lecky FE, Sutton A, Leaviss J & O'Cathain A (2016) . Injury, 47(6), 1170-1183.
• Leaviss J & Uttley L (2015) . Psychological Medicine, 45(05), 927-945.
• Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Cantrell A & Michaels J (2014) . Br J Surg, 101(9), 1040-1052.
• Leaviss J, Hummel S, Carroll C, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2014) Clinical and cost-effectiveness of minimally invasive techniques for the treatment of varicosis: Systematic review and economic evaluation. Vasomed, 26(4), 210-211.
• Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, Strong M & Cantrell A (2014) . Health Technol Assess, 18(33), 1-120.
• Fishwick D, Carroll C, McGregor M, Drury M, Webster J, Bradshaw L, Rick J & Leaviss J (2013) . Occup Med (Lond), 63(8), 526-536.
• Scope A, Leaviss J, Kaltenthaler E, Parry G, Sutcliffe P, Bradburn M & Cantrell A (2013) . BMC Psychiatry, 13, 321.
• Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2013) . Health Technol Assess, 17(48), i-141.
• Carroll C, Booth A, Leaviss J & Rick J (2013) . BMC Med Res Methodol, 13, 37.
• Carroll C, Rick J, Leaviss J, Fishwick D & Booth A (2013) . BMC Public Health, 13, 1095.
• Goodacre S, Thokala P, Carroll C, Stevens JW, Leaviss J, Al Khalaf M, Collinson P, Morris F, Evans P & Wang J (2013) . Health Technol Assess, 17(1), v-188.
• Carroll C, Khalaf MA, Stevens JW, Leaviss J, Goodacre S, Wang J & Collinson PO (2013) . Emergency Medicine Journal, 30(4), 280-286.
• Leaviss J, Gibb AGF & Bust PD (2008) Ageing workforce in construction - Equipment use and the prevention of early retirement. Contemporary Ergonomics 2008, 221-226.
• McManus IC, Iqbal S, Chandrarajan A, Ferguson E & Leaviss J (2005) . BMC Medical Education, 5.
• Ferguson E, Leaviss J, Townsend E, Fleming P & Lowe KC (2005) . Transfusion Medicine, 15(5), 401-412.
• Boaden N & Leaviss J (2000) . Medical Education, 34(11), 921-927.
• Leaviss J (2000) . Medical Education, 34(6), 483-486.
• GOUDIE AJ, LEAVISS J & LEATHLEY MJ (1995) EFFECT OF THE 5-HT3 ANTAGONIST ONDANSETRON ON CHLORDIAZEPOXIDE WITHDRAWAL HYPERTHERMIA. BRITISH JOURNAL OF PHARMACOLOGY, 114, P379-P379.
• Mellor J, Kuznetsov D, Heller S, Gall M-A, Rosilio M, Amiel SA, Ibberson M, McGurnaghan S, Blackbourn L, Berthon W , Salem A et al () . Diabetologia.
• Mellor J, Kuznetsov D, Heller S, Gall M-A, Rosilio M, Amiel SA, Ibberson M, McGurnaghan S, Blackbourn L, Berthon W , Salem A et al () . Diabetologia.

Conference proceedings papers

• Sutton A, Scope A, Leaviss J & Booth A (2018) . International Journal of Technology Assessment in Health Care, Vol. 33(S1) (pp 48-49). Cambridge, 17 June 2017 - 21 June 2017.
• Bessey A, Leaviss J, de la Cruz GC, Chilcott J & Wong R (2017) THE COST-EFFECTIVENESS OF SCREENING FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) IN THE UK NHS NEWBORN BLOODSPOT SCREENING PROGRAMME. VALUE IN HEALTH, Vol. 20(9) (pp A501-A501)
• Gibb A, Leaviss J & Bust P (2014) Older construction workers: Needs and abilities. Proceedings 29th Annual Association of Researchers in Construction Management Conference, ARCOM 2013 (pp 261-271)
• Gibb A, Leaviss J & Bust P (2013) Older construction workers: Needs and abilities. Proceedings 29th Annual Association of Researchers in Construction Management Conference, ARCOM 2013 (pp 261-271)
• Carroll C, Goodacre S, Stevens J, Al Khalaf M, Leaviss J, Wang J & Collinson P (2012) . VALUE IN HEALTH, Vol. 15(7) (pp A361-A361)

Reports

• Leaviss J, Harnan S, Pandor A & Cantrell A (2022) Newborn screening for congenital adrenal hyperplasia. External review against programme appraisal criteria for the UK National Screening Committee
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix J - Dementia.
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix K - Cardiovascular.
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix H - Psychological Therapies
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix I - Schizophrenia
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) . Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix F - Bowel Cancer.
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix E - Diabetes
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix G - Head and Neck Cancer.
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the collection patient reported outcome measures in the National Clinical Audits for assessing costeffectiveness Work Package 1. What patient reported outcome measures should be used in the 13 health conditions specified in the 2013/14 National Clinical Audit programme? APPENDIX C, INFLAMMATORY BOWEL DISEASE
• Ara , Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme. Appendix D - Epilepsy
• Ara R, Duarte A, Harnan S, Leaviss J, Palmer S, Sculpher M & Brazier JE (2015) Supporting the routine collection of patient reported outcome measures in the National Clinical Audits for assessing cost-effectiveness. Work Package 1. What patient reported outcome measures should be used in the 2013/14 National Clinical Audit Programme.
• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Part 2. Independent economic evaluation: methods and results, discussion and conclusion
• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Appendices.
• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Part 1, Executive summary, introduction, clinical reviews and conceptual modelling.

Posters

• Carroll C, Goodacre S, Stevens J & Leaviss J Diagnostic accuracy of early biomarkers for acute coronary syndrome (ACS) (2012).
• Leaviss J, Stevens J, J W, Goodacre S & F M Prognostic accuracy of Exercise ECG and CT Coronary Angiography to predict Major Adverse Cardiac Events (MACE) in patients with suspected Acute Coronary Syndrome (ACS): A systematic review (2012).

Other

• Carlton J, Leaviss J, Pouwer F, Hendrieckx C, Broadley MM, Clowes M, McCrimmon RJ, Heller SR & Speight J (2022) . Diabetologia.